{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:17:55Z","timestamp":1792534675337,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Olanzapine and fluvoxamine are commonly used psychotropic medications for treating anxiety and depressive disorders, particularly in cases with psychotic symptoms or treatment-resistant presentations. Although there are occasional reports of hematologic toxicity with monotherapy of these two drugs, no clear reports in the existing literature have documented severe sideroblastic anemia induced by their combination. Notably, as a potent CYP1A2 inhibitor, fluvoxamine significantly inhibits the metabolism of olanzapine, leading to elevated plasma concentrations. This pharmacokinetic synergy may exacerbate the risk of myelosuppression, although the specific mechanism remains to be elucidated. This article presents the first documented case of a 78-year-old male patient with chronic obstructive pulmonary disease (COPD) who developed severe anemia (nadir hemoglobin 37 g\/L) after the combined use of olanzapine and fluvoxamine. Through systematic etiological investigation, bone marrow morphology findings, and the Naranjo Adverse Drug Reaction Probability Scale (score 9, indicating a clear association), the diagnosis was confirmed as drug-induced severe acquired sideroblastic anemia. This case underscores the importance of thoroughly evaluating blood system safety when combining psychotropic medications in elderly patients with chronic diseases, and highlights the need for enhanced dynamic monitoring to identify and intervene in potential adverse reactions at an early stage.<\/jats:p>","DOI":"10.3389\/fpsyt.2025.1637065","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:44:49Z","timestamp":1757051089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug-induced severe sideroblastic anemia following combined olanzapine and fluvoxamine therapy: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Xinru","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161010-00011","article-title":"Olanzapine: an updated review of its use in the management of schizophrenia","volume":"61","author":"Bhana","year":"2001","journal-title":"Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753020-00007","article-title":"Olanzapine","volume":"53","author":"Fulton","year":"1997","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"CD001359","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","volume":"2005","author":"Duggan","year":"2005","journal-title":"Cochrane Database Systematic Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)03111-6","article-title":"Olanzapine-induced agranulocytosis","volume":"354","author":"Naumann","year":"1999","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000052093","article-title":"One further case of pancytopenia induced by olanzapine in a parkinson\u2019s disease patient","volume":"45","author":"Onofrj","year":"2001","journal-title":"Eur Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0788-3","article-title":"Olanzapine and pancytopenia with severe folate deficiency","volume":"66","author":"Maurier","year":"2010","journal-title":"Eur J Of Clin Pharmacol"},{"key":"B7","article-title":"Olanzapine-induced pancytopenia: a rare but worrying complication","volume":"27","author":"Pang","year":"2017","journal-title":"East Asian Arch Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/gpsych-2018-000013","article-title":"Olanzapine-induced leucopaenia and thrombocytopaenia in an elderly patient: a case report and review of the evidence","volume":"31","author":"Malik","year":"2018","journal-title":"Gen Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e74677","DOI":"10.7759\/cureus.74677","article-title":"Olanzapine-induced thrombocytopenia in a patient with chronic schizophrenia: a case report","volume":"16","author":"Bokhari","year":"2024","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcpeng.2021.10.005","article-title":"Haematological adverse effects associated with olanzapine in adolescents with anorexia nervosa: three case reports","volume":"53","author":"Bottoni-Tito","year":"2024","journal-title":"Rev Colombiana Psiquiatr\u00eda (english Ed.)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12888-025-06491-2","article-title":"Prevalence, sub-types, and associated factors of anemia among inpatients at a tertiary psychiatric hospital in Tanzania: a cross-sectional study","volume":"25","author":"Msigwa","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060040-00006","article-title":"Fluvoxamine","volume":"60","author":"Figgitt","year":"2000","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(92)90082-H","article-title":"Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement","volume":"25","author":"Celada","year":"1992","journal-title":"J Affect Disord"},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/archinte.163.1.59","article-title":"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: A population-based cohort study","volume":"163","author":"Dalton","year":"2003","journal-title":"Arch Internal Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.100912","article-title":"Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction","volume":"183","author":"Labos","year":"2011","journal-title":"CMAJ : Can Med Assoc J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-08-815951","article-title":"The molecular genetics of sideroblastic anemia","volume":"133","author":"Ducamp","year":"2019","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ajh.24637","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T) \u2013 \u201c2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine: pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200210000-00010","article-title":"Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects","volume":"22","author":"Hiemke","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2004.01269.x","article-title":"Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia","volume":"58","author":"Chaichan","year":"2004","journal-title":"Psychiatry Clin Neurosci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004270291","article-title":"Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia","volume":"44","author":"Chiu","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004266621","article-title":"The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers","volume":"44","author":"Wang","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/01.jcp.0000155825.97703.01","article-title":"Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy","volume":"25","author":"Albers","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.711940","article-title":"Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone","volume":"12","author":"Soria-Chacartegui","year":"2021","journal-title":"Front Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200108000-00015","article-title":"Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service","volume":"23","author":"Weigmann","year":"2001","journal-title":"Ther Drug Monit"},{"key":"B28","doi-asserted-by":"publisher","first-page":"106050","DOI":"10.1016\/j.ypmed.2020.106050","article-title":"Depression, antidepressants and low hemoglobin level in the Paris prospective study III: a cross-sectional analysis","volume":"135","author":"Vulser","year":"2020","journal-title":"Prev Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2006.8.1217","article-title":"SOD2-deficiency sideroblastic anemia and red blood cell oxidative stress","volume":"8","author":"Martin","year":"2006","journal-title":"Antioxidants Redox Signaling"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/genes13091562","article-title":"Causes and pathophysiology of acquired sideroblastic anemia","volume":"13","author":"Rodriguez-Sevilla","year":"2022","journal-title":"Genes"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19185","DOI":"10.1038\/s41598-020-75356-3","article-title":"N-acetylcysteine prevents olanzapine-induced oxidative stress in mHypoA-59 hypothalamic neurons","volume":"10","author":"Boz","year":"2020","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"11119","DOI":"10.3390\/ijms252011119","article-title":"Aripiprazole, but not olanzapine, alters the response to oxidative stress in fao cells by reducing the activation of mitogen-activated protein kinases (MAPKs) and promoting cell survival","volume":"25","author":"Kramar","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.3324\/haematol.2013.092395","article-title":"Linezolid induces ring sideroblasts","volume":"98","author":"Willekens","year":"2013","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.06.017","article-title":"The unfolded protein response and cell fate control","volume":"69","author":"Hetz","year":"2018","journal-title":"Mol Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70695","DOI":"10.1096\/fj.202500228R","article-title":"CD44 deficiency induces combinatory NRF2 inhibition and endoplasmic reticulum stress-associated dyserythropoiesis","volume":"39","author":"Yang","year":"2025","journal-title":"FASEB J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0250-z","article-title":"Mechanisms, regulation and functions of the unfolded protein response","volume":"21","author":"Hetz","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60970","article-title":"Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes","volume":"9","author":"Ninagawa","year":"2020","journal-title":"Elife"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01305-6","article-title":"DNMT1 regulates human erythropoiesis by modulating cell cycle and endoplasmic reticulum stress in a stage-specific manner","volume":"31","author":"Yang","year":"2024","journal-title":"Cell Death differentiation"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.03.011","article-title":"Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response","volume":"94","author":"Anusornvongchai","year":"2018","journal-title":"Kidney Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1247\/csf.13012","article-title":"The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic \u03b2 cells by blocking PERK-mediated translational attenuation","volume":"38","author":"Ozasa","year":"2013","journal-title":"Cell Structure Funct"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.589650","article-title":"Olanzapine-induced activation of hypothalamic astrocytes and toll-like receptor-4 signaling via endoplasmic reticulum stress were related to olanzapine-induced weight gain","volume":"14","author":"He","year":"2021","journal-title":"Front Neurosci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-023-01180-w","article-title":"Activation of the PERK-CHOP signaling pathway during endoplasmic reticulum stress contributes to olanzapine-induced dyslipidemia","volume":"45","author":"Liu","year":"2024","journal-title":"Acta Pharmacologica Sin"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.02.014","article-title":"Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates","volume":"634","author":"Mishra","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4103\/mjdrdypu.mjdrdypu_13_24","article-title":"Olanzapine-induced pancytopenia: case report","volume":"17","author":"Prajnashree","year":"2024","journal-title":"Med J Dr. D.Y. Patil Vidyapeeth"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001977","article-title":"Bicytopenia in the context of olanzapine treatment","volume":"45","author":"MY","year":"2025","journal-title":"J Clin Psychopharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1637065\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T05:44:50Z","timestamp":1757051090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1637065\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":45,"alternative-id":["10.3389\/fpsyt.2025.1637065"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1637065","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"article-number":"1637065"}}